ABSTRACT
· AIM:To analyze the clinical effect of intravitreal injection of Conbercept combined with retinal laser photocoagulation in the treatment of patients with diabetic macular edema (DME).· METHODS:Totally 73 patients (80 eyes) with type 2 diabetes and DME were enrolled in our hospital from June 2015 to December 2016,according to different treatment methods,and they were randomly divided into control group and treatment group.The control group were treated with retinal laser photocoagulation,and the treatment group were treated with intravitreal injection combined with laser photocoagulation.We observed the best corrected visual acuity (BCVA),retinal thickness and complications during the operation before treatment and 3mo after treatment.· RESULTS:At 3mo after treatment,the improvement of BCVA,the decreased value of average retinal thickness and retinal thickness at inferior,superior,temple and nasal in the treatment group were better than those in the control group and those after treatment was better than before(P＜ 0.05).There was no statistically significant difference in the incidence of complications occurrence between the two groups (P＞0.05).None of the patients had severe ocular complications such as corneal edema,anterior chamber inflammatory reaction,retinal hemorrhage,neonatal vascular glaucoma,endophthalmitis,etc.during follow up period.· CONCLUSION:Compared with applying laser photocoagulation alone,intravitreal injection of conbercept combined for DME is more effective with improved visual acuity,restored retinal function,and has good safety.
ABSTRACT
·AIM:To evaluate the efficacy and safety of intravitreal injection of Conbercept as the treatment of choroidal neovascularization due to high myopia. ·METHODS: The study was a retrospective analytical case series. We reviewed medical records of 15 patients (16 eyes) with choroidal neovascularization second to high myopia that had enrolled in our hospital from January 2013 to December 2016. All patients have received one or more conbercept injections based on medical condition and observed the best corrected visual acuity (BCVA) and macular retinal thickness before and after the last injection. The duration of the last follow-up was from 1.5mo to 28mo. ·RESULTS:Totally 15 patients(16 eyes) were enrolled in this study. All patients received conbercept injections. Among all the patients,6 eyes were given one treatment, 7 eyes were given two treatments and 3 eyes three treatments. Before retreatment, the mean intraocular pressure was 16.44±1.39mmHg before treatment,and the average intraocular pressure was 16.75 ± 1.41mmHg after the last treatment. The difference was not statistically significant (P> 0. 05). BCVA was 1. 14 ± 0. 35 before treatment,BCVA was 0.71±0.21 at the last follow-up. The difference was statistically significant (P< 0. 05). The thickness of the macular retina was 361. 63 ± 33. 59μ m before treatment,and it was 287.25 ± 30.31μ m at the last follow-up, and the difference was statistically significant (P<0.05). And there was no case of endophthalmitis, stroke,and retinal detachment during follow-up. ·CONCLUSION: Intravitreal injection of conbercept can effectively improve the patient's BCVA in the short term and reduce the macular fovea retinal thickness. No significant adverse events are observed.
ABSTRACT
BACKGROUND: To mimic physiological and functional requirements of cartilage and subcondral bone, some recent studies have fabricated bilayered scaffolds for osteochondral tissue engineering in cartilage repair. However, in cartilage repair, and little is reported on the use of a single biomaterial instead of composite biomaterials to fabricate bilayered porous scaffolds. OBJECTIVE: To investigate the biocompatibility of an integrated bilayered porous scaffold fabricated with poly(lactic-co-glycolide) (PLGA), and then to discuss its feasibility of constructing tissue-engineered osteochondral graft. METHODS: The integrated bilayered porous scaffolds were fabricated with PLGA by changing the ultrastructure of scaffold.In vitro,bone marrow mesenchymal stem cells(BMSCs)isolated from rabbits were seeded into the bilayered porous PLGA scaffold, co-cultured for 1 week and then observed under scanning electron microscope. After co-culturing 48 hours,the cells were stained by LIVE/DEAD Kit.In vivo,the composite of DiI-labeled BMSCs and the scaffold or the scaffold alone were implanted subcutaneously into the skin of nude mice, and the implants were taken out and stained by hematoxylin-eosin and DAPI staining at 4 and 8 weeks after implantation. RESULTS AND CONCLUSION: (1) We successfully obtained the bilayered porous scaffolds with different pore sizes (the upper layer:100-200 μm and the lower layer:300-450 μm)and 85% porosity.(2)In the in vitro experiment,the LIVE/DEAD staining showed that BMSCs survived well in the scaffold, and the cells adhered well to the wall of pores in all the scaffolds and extracellular matrix deposition was found under the scanning electron microscope.(3)In the in vivo experiment, shown by the hematoxylin-eosin staining, a small amount of chondrocytes formed in the fibrous tissue in the upper layer and a large amount of trabecular bones in the lower layer were found at 8 weeks after implantation in the experimental group. The close integration between the upper layer and the lower layer appeared. BMSCs could survive for 8 weeks in vivo shown by the DAPI staining.However,in the control group,a little fibrous tissue was found without chondrocytes and apparent trabecular bone, and the scaffold was partially degraded. To conclude, the integrated bilayered porous scaffold fabricated with PLGA alone has good biocompatibility, which is feasibly used in osteochondral tissue engineering.